NCT05704621View on ClinicalTrials.gov

Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance

PHASE2RecruitingINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

December 28, 2026

Study Completion Date

December 28, 2028

Conditions
Ovarian CancerDrug Related Neoplasm/Cancer
Interventions
PROCEDURE

secondary cytoreductive surgery

Maximum effort cytoreductive surgery

DRUG

chemotherapy

six cycles of platinum-based chemotherapy +/- bevacizumab

Trial Locations (1)

Unknown

RECRUITING

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
collaborator

Boryung Pharmaceutical Co., Ltd

INDUSTRY

collaborator

Chong Kun Dang Pharmaceutical Corp.

INDUSTRY

collaborator

Yonsei University

OTHER

collaborator

KGOG: Korean Gynaelogical Onology Group, Korea

UNKNOWN

collaborator

Japanese Gynecologic Oncology Group

OTHER

collaborator

Asia-Pacific Gynecologic Oncology Trials Group (APGOT)

UNKNOWN

lead

Korea University Guro Hospital

OTHER

NCT05704621 - Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance | Biotech Hunter | Biotech Hunter